Introduction: Influenza A H1N1 community-acquired pneumonia (CAP) is a quite frequent respiratory disease. Despite being considered more serious than other CAPs, there are very few studies comparing its characteristics with noninfluenza CAP. We aim to establish the differences between pneumonia due to H1N1 virus and pneumonia not caused by H1N1 influenza virus and to determine the probability that a pneumonia is due to an H1N1 virus infection based on the most relevant variables.

Methods: We used a case-control study where cases were H1N1 CAP patients with confirmed microbiological diagnosis and controls were patients with CAP admitted to hospital. H1N1 and other influenza types were discarded among controls. We calculated the probability of being a case or control using multivariate logistic regression.

Results: We included 99 cases and 270 controls. Cases were younger than controls (53 vs 71 years, respectively). Mortality was much higher for H1N1 patients (13% vs 0.3%), and admission to intensive care unit was more frequent for H1N1 cases. The variables most associated with presenting H1N1 CAP were bilateral affectation on chest X-rays (OR: 5.70; 95% CI 2.69-10.40), followed by presence of arthromyalgias, with cases presenting close to three times more arthromyalgias compared to controls. Low leukocytes count and high AST values were also significantly associated with H1N1 CAP. H1N1 CAPs are characterized by bilateral affectation, low leukocyte count, presence of arthromyalgias, and high AST.

Conclusions: A few and easy to obtain clinical parameters might be extremely useful to distinguish H1N1 CAP from CAPs of other origin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441515PMC
http://dx.doi.org/10.1155/2019/4301039DOI Listing

Publication Analysis

Top Keywords

h1n1 cap
16
h1n1
12
influenza h1n1
8
h1n1 community-acquired
8
community-acquired pneumonia
8
case-control study
8
pneumonia h1n1
8
h1n1 virus
8
h1n1 influenza
8
bilateral affectation
8

Similar Publications

Discovery of Novel Thiophene-Based Baloxavir Derivatives as Potent Cap-Dependent Endonuclease Inhibitors for Influenza Treatment.

J Med Chem

December 2024

Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, Shenzhen Grubbs Institute and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen 518000, China.

The genetic recombination and antigenic variation of influenza viruses may decrease the efficacy of antiviral vaccines, highlighting the imperativeness of developing novel anti-influenza agents. Herein, a series of thiophene-based compounds were designed and synthesized as potent anti-influenza agents. Among them, exhibited an excellent anti-influenza activity (EC, H1N1 = 1.

View Article and Find Full Text PDF
Article Synopsis
  • - Since 2013, there have been 167 cases of people infected with special flu viruses from pigs in the U.S. called swine-origin influenza A.
  • - Most of these viruses had a change in their genes that makes them resistant to certain medicines, but none were resistant to another type of medicine called neuraminidase inhibitors.
  • - Scientists did tests to find out how well these viruses respond to treatments and discovered that one specific change in the virus made it much harder to treat with a medicine called baloxavir.
View Article and Find Full Text PDF

Baloxavir acid (BXA) is a pan-influenza antiviral that targets the cap-dependent endonuclease of the polymerase acidic (PA) protein required for viral mRNA synthesis. To gain a comprehensive understanding on the molecular changes associated with reduced susceptibility to BXA and their fitness profile, we performed a deep mutational scanning at the PA endonuclease domain of an A (H1N1)pdm09 virus. The recombinant virus libraries were serially passaged in vitro under increasing concentrations of BXA followed by next-generation sequencing to monitor PA amino acid substitutions with increased detection frequencies.

View Article and Find Full Text PDF

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients.

Int J Infect Dis

September 2024

Division of Virology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Department of Pathobiological Sciences, School of Veterinary Medicine, Influenza Research Institute, University of Wisconsin-Madison, Madison, WI, USA; Pandemic Preparedness, Infection, and Advanced Research Center, The University of Tokyo, Tokyo, Japan.

Article Synopsis
  • * Research on the viruses showed that they were susceptible to various antiviral medications, including remdesivir and oseltamivir, without mutations that could lead to reduced effectiveness of these treatments.
  • * Despite the co-infections, the treated patients did not experience severe symptoms, highlighting the importance of ongoing monitoring of these viruses as they evolve to inform public health strategies.
View Article and Find Full Text PDF

Lefamulin is a first-in-class systemic pleuromutilin antimicrobial and potent inhibitor of bacterial translation, and the most recent novel antimicrobial approved for the treatment of community-acquired pneumonia (CAP). It exhibits potent antibacterial activity against the most prevalent bacterial pathogens that cause typical and atypical pneumonia and other infectious diseases. Early studies indicate additional anti-inflammatory activity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!